Biotechnology company Shire said it highlighted its research results on the unmet and changing needs of adults affected by attention-deficit/hyperactivity disorder (ADHD) at the annual meeting of the American Psychiatric Association (APA) held earlier this month in San Diego.
“The data being presented this year at APA by Shire help us to better understand the needs of adults with ADHD, a disorder that can impair adults in home, social and work settings,” Norman Atkins, medical lead for ADHD at Shire, said in a release. “Based on our research, we understand that symptom burden can persist in adults with ADHD, including those who have been working with their health care professional to manage the disorder. We want to advance the understanding of the complex needs of adults with ADHD and how we can best address those.”
Study results offered included information on symptom burden and the need to identify ADHD in adults and treat it more efficiently, Shire said.
“Research was also presented on SHP465 (mixed salts of a single-entity amphetamine product), an investigational agent currently under review with the U.S. Food and Drug Administration (FDA) as a potential treatment for ADHD,” Shire said in the release. “In addition, research was presented on Vyvanse (lisdexamfetamine dimesylate), an approved treatment option for patients 6 years old and above with ADHD.”
